Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 10/20 | 0.76 |
| ▸ | NPC1 | O15118 | 9/20 | 0.76 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.76 |
| ▸ | POLB | P06746 | 1/20 | 0.76 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.76 |
| ▸ | TP53 | P04637 | 3/20 | 0.70 |
| ▸ | TSHR | P16473 | 1/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.68 |
| ▸ | MEN1 | O00255 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.68 |
| ▸ | GAA | P10253 | 1/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.68 |
| ▸ | HTT | P42858 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7686538 | 0.89 | RAB9A (0.72) | RAB9ANPC1SMN1; SMN2POLBTDP1 | |
| SCHEMBL2245506 | 0.87 | RAB9A (1.00) | RAB9ANPC1SMN1; SMN2POLBTDP1 | |
| SCHEMBL2241896 | 0.83 | RAB9A (1.00) | RAB9ANPC1SMN1; SMN2POLBTDP1 | |
| SCHEMBL5007637 | 0.81 | NPC1 (1.00) | RAB9ANPC1SMN1; SMN2POLBTDP1 | |
| SCHEMBL2242937 | 0.79 | RAB9A (0.70) | RAB9ANPC1SMN1; SMN2POLBTDP1 | |
| SCHEMBL7686239 | 0.78 | GRIN1 (0.49) | RAB9ANPC1SMN1; SMN2POLBTDP1 | |
| SCHEMBL7963333 | 0.78 | RAB9A (0.48) | RAB9ANPC1SMN1; SMN2POLBTDP1 | |
| SCHEMBL7689249 | 0.78 | RAB9A (0.48) | RAB9ANPC1SMN1; SMN2POLBTDP1 | |
| SCHEMBL7686234 | 0.78 | RAB9A (0.48) | RAB9ANPC1SMN1; SMN2POLBTDP1 | |
| SCHEMBL2248644 | 0.78 | NPC1 (1.00) | RAB9ANPC1SMN1; SMN2POLBTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020007071-A1 | Benzimidzolyl neuropeptide Y receptor antagonists | BRITTON THOMAS CHARLES (US) | 2002-01-17 | — | — | US | disclosed |
| US-6255494-B1 | SUBSTITUTED BENZIMIDAZOLES USEFUL IN TREATING OR PREVENTING CONDITIONS ASSOCIATED WITH EXCESS OF NEUROPEPTIDE Y (AROUND ARTERIES IN HEART, RESPIRATORY TRACT, GASTROINTESTINAL TRACT AND GENITOURINARY TRACT); ETIOLOGY OF PSYCHIATRIC DISORDERS | ELI LILLY AND COMPANY | 2001-07-03 | — | — | US | disclosed |
| EP-0871442-A1 | BENZIMIDZOLYL NEUROPEPTIDE Y RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1998-10-21 | — | — | EP | disclosed |
| WO-1997025041-A1 | BENZIMIDZOLYL NEUROPEPTIDE Y RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1997-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020007071-A1 | Benzimidzolyl neuropeptide Y receptor antagonists | NPY1R, NPY2R, NPY5R | RAB9A 3072/4885NPC1 1857/4885SMN1; SMN2 2698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.